Hesperidin for Heart & Blood Pressure

The same single layer of cells that hesperidin protects inside veins — the endothelium — also lines every artery in the body, and that is the bridge from hesperidin's venous reputation to its cardiovascular research. In test tubes, the absorbed form of hesperidin coaxes endothelial cells to make more nitric oxide, the molecule that relaxes and protects arteries. In people, hesperidin-rich orange juice has improved endothelial function and shaved a few points off blood pressure in several controlled trials. This is genuinely interesting work, but it deserves honest framing: the effects are small, they are measured mostly on surrogate markers rather than heart attacks or strokes, the trials are short, and not every study is positive. This page walks through the landmark trials, the mechanism, and exactly where the evidence is strong and where it is thin.

Table of Contents

  1. From Veins to Arteries: the Same Endothelium
  2. Endothelial Function and Nitric Oxide
  3. The Morand Orange-Juice Trial
  4. The Rizza Metabolic-Syndrome Trial
  5. Blood Pressure: What the Trials Show
  6. Cholesterol and Lipids
  7. Inflammation and Cardiometabolic Markers
  8. Preclinical Cardioprotection
  9. Honest Limits: Small Effects, Surrogate Markers, Orange Juice vs Supplement
  10. Practical Takeaways
  11. Key Research Papers
  12. Connections
  13. Featured Videos

From Veins to Arteries: the Same Endothelium

Hesperidin's venous benefits come largely from protecting the venous endothelium — reducing inflammation, leakiness, and leukocyte injury in the vein wall. Arteries are lined by the same endothelium, so it is a natural scientific question whether the molecule does anything useful on the arterial side, where the stakes are higher: arterial endothelial dysfunction is one of the earliest, most reversible steps on the road to atherosclerosis, high blood pressure, and cardiovascular disease.

The answer from human trials is a cautious yes — hesperidin appears to nudge arterial biology in a favorable direction — but the magnitude is modest and the outcomes measured are early-warning markers rather than clinical events. Keeping those two facts in mind is the difference between an accurate picture and hype.

Back to Table of Contents

Endothelial Function and Nitric Oxide

The endothelium is not just plumbing lining. It is an active organ that senses blood flow and releases signals, the most important of which is nitric oxide (NO). When endothelial cells make NO through the enzyme eNOS, the NO diffuses into the surrounding muscle of the artery wall and tells it to relax. That relaxation widens the artery, lowers resistance, and reduces blood pressure. NO also keeps platelets from clumping and discourages inflammatory cells from sticking — so healthy NO signaling is anti-clot and anti-atherosclerosis as well as blood-pressure-lowering.

Doctors and researchers gauge this system with flow-mediated dilation (FMD): they briefly cuff off blood flow to the forearm, release it, and measure how much the brachial artery widens in response to the rush of flow. A bigger, healthier dilation means better endothelial NO function. Much of the hesperidin cardiovascular literature is built on FMD and related microvascular-reactivity measures.

The mechanistic link is direct: in cultured human endothelial cells, hesperetin (the absorbed aglycone form of hesperidin) increases NO production. Rizza and colleagues showed exactly this in their laboratory work alongside their clinical trial, giving a plausible molecular reason for the improvements they saw in patients.

Back to Table of Contents

The Morand Orange-Juice Trial

The trial that put hesperidin on the cardiovascular map was published by Morand and colleagues in the American Journal of Clinical Nutrition. It was a well-designed randomized, controlled, crossover study in middle-aged, overweight-to-mildly-obese men — a group with early cardiovascular risk but not established disease.

The clever part of the design was a three-way comparison that isolated hesperidin as the active ingredient. Participants drank, in random order over separate periods: (1) orange juice, (2) a control drink spiked with pure hesperidin at the same amount found in the juice, and (3) a control drink with no hesperidin (placebo). Both the orange juice and the hesperidin-spiked drink improved postprandial microvascular endothelial reactivity and lowered diastolic blood pressure compared with placebo, while the two hesperidin-containing drinks behaved similarly to each other.

The interpretation was elegant: hesperidin is a genuine active vascular ingredient of orange juice, not just a bystander riding along with the vitamin C and sugar. That single result is why so many follow-up trials used orange juice or purified hesperidin to probe blood pressure and endothelial function.

Back to Table of Contents

The Rizza Metabolic-Syndrome Trial

Where Morand studied healthy-ish men, Rizza and colleagues tested people who already had metabolic syndrome — the cluster of abdominal obesity, high blood pressure, high blood sugar, and abnormal lipids that markedly raises cardiovascular risk. In a randomized, placebo-controlled crossover trial published in the Journal of Clinical Endocrinology & Metabolism, participants took 500 mg of hesperidin daily for three weeks.

Compared with placebo, hesperidin improved flow-mediated dilation and lowered several markers of vascular inflammation, including high-sensitivity C-reactive protein (hs-CRP), serum amyloid A, and soluble E-selectin (a molecule endothelial cells use to grab inflammatory cells). Paired with their cell-culture demonstration that hesperetin boosts endothelial NO, the trial offered a coherent mechanism-plus-outcome package: hesperidin makes the endothelium calmer and more responsive in exactly the population that needs it.

It is still a short trial in a small group measuring surrogate markers — but it is one of the more compelling pieces of the hesperidin cardiovascular case.

Back to Table of Contents

Blood Pressure: What the Trials Show

Blood pressure is where patients most want a number, so here is the honest version. Several trials show a small reduction; some show none.

A 2025 systematic review and meta-analysis by Heidari and colleagues pooling hesperidin trials on cardiometabolic markers found effects that were, on balance, small and inconsistent across outcomes. The fair summary: in people with elevated blood pressure or metabolic risk, hesperidin may lower blood pressure by a few millimeters of mercury; in already-healthy people, the effect is often undetectable. This is a helpful dietary nudge, not a substitute for antihypertensive medication when that is indicated — see our Hypertension page.

Back to Table of Contents

Cholesterol and Lipids

The lipid story is the weakest part of the cardiovascular case, and honesty requires saying so. Some trials and animal studies suggest hesperidin can modestly lower total and LDL cholesterol or triglycerides, plausibly by influencing cholesterol-handling enzymes in the liver. But the human results are inconsistent, and a systematic review by Mohammadi and colleagues concluded that hesperidin might not meaningfully affect the lipid profile or blood pressure across the available trials.

The practical reading is not to count on hesperidin for cholesterol control. If your goal is lipid improvement, the interventions with strong evidence — diet pattern, fiber, exercise, weight change, and where appropriate statins — are where the real leverage is. Hesperidin, at most, is a small tailwind.

Back to Table of Contents

Inflammation and Cardiometabolic Markers

A recurring, relatively consistent thread across the trials is a reduction in inflammatory markers. Rizza saw lower hs-CRP and serum amyloid A; Homayouni saw lower inflammatory markers in diabetes; and Haidari and colleagues reported that hesperidin supplementation modulated inflammatory responses in patients recovering from myocardial infarction (heart attack). Because chronic low-grade inflammation is a driver of atherosclerosis, this anti-inflammatory signal is biologically encouraging.

There is also mechanistic support for protecting the endothelium against the daily insults of eating. Rendeiro and colleagues showed that flavanone-rich citrus beverages blunted the transient dip in endothelial function that normally follows a high-fat meal — a real-world stress test of the vasculature. The deeper cellular machinery behind these anti-inflammatory effects — the Nrf2 and NF-κB pathways — is covered on the Antioxidant & Anti-Inflammatory page.

Back to Table of Contents

Preclinical Cardioprotection

A large body of animal and cell research suggests hesperidin can protect heart tissue from injury, particularly the damage that occurs when blood flow is restored after a period of blockage (ischemia-reperfusion injury, the situation during a heart attack and its treatment). For example, Li and colleagues found that short-term hesperidin pretreatment reduced myocardial ischemia-reperfusion injury in rats, apparently by limiting oxidative stress and cell death.

This kind of result is mechanistically illuminating and consistent with hesperidin's antioxidant biology — but it must be read for what it is. Animal and cell studies do not establish a human benefit. They generate hypotheses and explain mechanisms; they do not tell a person that taking hesperidin will protect their heart during a cardiac event. We include preclinical work here for completeness and to explain the biology, not as a clinical claim.

Back to Table of Contents

Honest Limits: Small Effects, Surrogate Markers, Orange Juice vs Supplement

Three caveats should travel with every optimistic sentence on this page:

  1. Surrogate markers, not events. The trials measure flow-mediated dilation, blood pressure, and inflammatory proteins — useful early indicators, but not the same as fewer heart attacks or strokes. No trial has shown that hesperidin reduces hard cardiovascular outcomes, and we should not imply that it does.
  2. Small and variable effects. Where benefits appear, they are modest and depend on the population (more visible in people with metabolic risk than in the healthy) and on the individual's ability to absorb hesperidin, which varies enormously with gut bacteria — see Sources & Absorption.
  3. The orange-juice confound. Many trials deliver hesperidin as orange juice, which also contains sugar, vitamin C, potassium, folate, and other compounds. The Morand three-arm design helps isolate hesperidin, but "drink more orange juice" is not automatically good cardiovascular advice given its sugar content — a whole orange, with its fiber and richer pith-and-membrane hesperidin, is generally the better package.

Back to Table of Contents

Practical Takeaways

Back to Table of Contents

Key Research Papers

  1. Morand C, et al. (2011). Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr. — PubMed 21068346
  2. Rizza S, et al. (2011). Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. — PubMed 21346065
  3. Salden BN, et al. (2016). Randomized clinical trial on the efficacy of hesperidin 2S on validated cardiovascular biomarkers in healthy overweight individuals. Am J Clin Nutr. — PubMed 27797708
  4. Homayouni F, et al. (2018). Blood pressure lowering and anti-inflammatory effects of hesperidin in type 2 diabetes. Phytother Res. — PubMed 29468764
  5. Valls RM, et al. (2021). Effects of hesperidin in orange juice on blood and pulse pressures in mildly hypertensive individuals. Eur J Nutr. — PubMed 32661681
  6. Pla-Pagà L, et al. (2021). Effects of hesperidin consumption on the cardiovascular system in pre- and stage 1 hypertensive subjects. Mol Nutr Food Res. — PubMed 34272817
  7. Heidari Z, et al. (2025). Effects of hesperidin supplementation on cardiometabolic markers: a systematic review and meta-analysis. Nutr Rev. — PubMed 39038797
  8. Mohammadi M, et al. (2019). Hesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure: a systematic review. Phytother Res. — PubMed 30632207
  9. Rendeiro C, et al. (2016). Flavanone-rich citrus beverages counteract the transient decline in postprandial endothelial function in humans. Br J Nutr. — PubMed 28065188
  10. Haidari F, et al. (2015). Hesperidin supplementation modulates inflammatory responses following myocardial infarction. J Am Coll Nutr. — PubMed 25757593
  11. Li X, et al. (2016). Short-term hesperidin pretreatment attenuates rat myocardial ischemia/reperfusion injury (preclinical, animal). Cell Physiol Biochem. — PubMed 27744432

PubMed Topic Searches

  1. PubMed: Hesperidin & endothelial function
  2. PubMed: Hesperidin & blood pressure (RCTs)
  3. PubMed: Orange juice, hesperidin & cardiovascular
  4. PubMed: Hesperidin & metabolic syndrome
  5. PubMed: Hesperetin, nitric oxide & eNOS

External Resources

Back to Table of Contents

Connections

Back to Table of Contents